List of Excipients in Branded Drug ECONAZOLE NITRATE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Trifluent Pharma LLC	ECONAZOLE NITRATE	econazole nitrate	73352-100	BUTANE
Trifluent Pharma LLC	ECONAZOLE NITRATE	econazole nitrate	73352-100	DIMETHICONE
Trifluent Pharma LLC	ECONAZOLE NITRATE	econazole nitrate	73352-100	GLYCERIN
Trifluent Pharma LLC	ECONAZOLE NITRATE	econazole nitrate	73352-100	POLYSORBATE 20

Generic Drugs Containing ECONAZOLE NITRATE

Company	Ingredient	NDC	Excipient
Rebel Distributors Corp	econazole nitrate	21695-892	BENZOIC ACID
Rebel Distributors Corp	econazole nitrate	21695-892	BUTYLATED HYDROXYANISOLE
Rebel Distributors Corp	econazole nitrate	21695-892	MINERAL OIL
Rebel Distributors Corp	econazole nitrate	21695-892	WATER

What are the Most Frequently-Used Excipients in ECONAZOLE NITRATE?

# Of NDCs	Excipient
4	APRICOT KERNEL OIL PEG-6 ESTERS
18	BENZOIC ACID
14	BUTYLATED HYDROXYANISOLE
4	BUTYLATED HYDROXYTOLUENE

Excipient Strategy and Commercial Opportunities for Econazole Nitrate

Last updated: February 26, 2026

What are the key considerations for excipient selection in econazole nitrate formulations?

Econazole nitrate requires specific excipients to optimize stability, bioavailability, and patient tolerability. The formulation typically involves:

• Creams and Topical Gels: Oil-in-water emulsions with excipients such as cetostearyl alcohol, lanolin, glycerin, and preservatives to enhance stability and ease of application.
• Supplements or Powders: Microcrystalline cellulose or other fillers to ensure proper dosage and handling.
• Solubilizers: Propylene glycol or polyethylene glycol (PEG) to improve solubility in topical formulations.

Selection criteria include compatibility with active ingredient, chemical stability, non-irritant properties, and regulatory acceptance. Excipients influence manufacturing processes, shelf life, and patient adherence.

How does excipient strategy affect formulation development and market growth?

A strategic excipient approach impacts:

• Product stability: Use of antioxidants (e.g., butylated hydroxytoluene) prevents degradation.
• Bioavailability: Compatible surfactants and solubilizers enhance drug penetration.
• Patient compliance: Non-irritating, odorless, and easy-to-apply formulations increase market acceptance.
• Regulatory ease: Use of approved excipients facilitates faster approval timelines.

Manufacturers with innovative excipient combinations can differentiate products, enabling premium pricing and expanded indications.

What are the commercial opportunities tied to excipient innovation in econazole nitrate products?

Opportunities include:

• Enhanced dosage forms: Development of foam, gel, or controlled-release formulations addresses unmet patient needs, especially in resistant infections.
• Formulation patents: Proprietary excipient combinations can create barriers to generics, preserving market share.
• Global expansion: Formulations using excipients compliant with international standards (e.g., USP, EMA) open access to emerging markets.
• Patient-centric products: Non-greasy, quick-drying formulations increase penetration in pediatric and geriatric segments.

Companies investing in novel excipient combinations can command higher margins and establish brand loyalty.

How do excipient regulatory considerations influence market entry?

Regulatory agencies closely scrutinize excipient safety and origin. Key points include:

• Approval status: Only excipients with established safety profiles can be used in marketed products.
• Regional variations: Regulatory frameworks differ (e.g., FDA, EMA, PMDA). Formulations must meet regional standards.
• Transparency: Detailed documentation of excipient sources and compatibility is required for registration.
• Toxicological data: New excipients or novel combinations necessitate safety testing, delaying time-to-market.

Aligning excipient strategies with regulatory pathways reduces risk and accelerates commercialization.

What are the implications of excipient choices on production and supply chain?

Excipient sourcing impacts:

• Cost: Use of high-purity or specialized excipients increases production expenses.
• Availability: Global supply chain disruptions, such as during pandemics, can limit access.
• Quality control: Consistent quality of excipients ensures batch-to-batch uniformity.
• Scale-up: Compatibility of excipients with manufacturing equipment influences scalability.

Developing relationships with multiple suppliers and adopting flexible formulation strategies mitigate risks.

Key Takeaways

• Excipient selection critically influences econazole nitrate's product stability, bioavailability, and patient acceptance.
• Strategic excipient innovation can create proprietary advantages and open new markets.
• Regulatory compliance of excipients determines regional market entry speed.
• Supply chain management of excipients affects production costs and scalability.
• Formulation flexibility facilitates expanding into novel dosage forms and indications.

FAQs

Q1: What are common excipients in econazole nitrate topical formulations?
Common excipients include preservatives, emulsifiers (cetostearyl alcohol), stabilizers, and penetration enhancers like propylene glycol.

Q2: Can novel excipients improve econazole nitrate formulations?
Yes. Novel excipients may enhance stability, permeability, or patient experience but require safety validation and regulatory approval.

Q3: How do excipient choices influence product patentability?
Patent protection can extend to specific excipient combinations or formulations, creating market exclusivity beyond the active ingredient.

Q4: What regulatory hurdles exist for excipient innovation?
New excipients require toxicology data and must be approved by authorities like FDA or EMA before use.

Q5: How does excipient supply chain resilience impact commercialization?
Disruptions increase costs and delay launches. Diversified sourcing and inventory management are critical.

---

References

[1] U.S. Food and Drug Administration. (2021). Guidance for Industry: Excipients in Drug Products.
[2] EMA. (2020). Guideline on Quality of Topical and Transdermal Preparations.
[3] WHO. (2019). WHO Model List of Essential Medicines.